1. HBW Insight
  2. >>Digital Technologies

VeriSIM Expects AI Use To Trim Margin For Failure In OTC Switches, Help Boost Revenue Margins

 
• By Malcolm Spicer

“It's a very expensive process for an OTC drug because you don't make significantly high margins compared to a blockbuster cancer drug. For pharma companies utilizing our platform, you can reduce that efficiency challenge and increase the probability of success,” says VeriSIM CEO Jo Varshney.

• Source: Shutterstock

Expectations for artificial intelligence’s use in pharma research typically skew heavily on ingredients which would be Rx-only, but firms looking at making additional drugs available OTC could have as much or more to gain.

Jo Varshney, founder and CEO of AI startup VeriSIM Life Inc., recently told HBW Insight that firms moving ingredients from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from HBW Insight

Trump’s Latest Tariff Order Reheats Consumer Worries And Price Increases In Healthcare Sector

 
• By Malcolm Spicer

When consumer health and beauty firms announce results for current quarter, they likely will note trend many reported after first quarter, an uptick in revenues and volume due to consumer concern about Trump’s tariffs gambit leading to higher product prices.

GSCF: ‘No One Size Fits All’ Solution To Tricky Sustainable Blister Pack Challenge

 
• By David Ridley

A series of research papers recently published by the Global Self-Care Federation indicate that industry will need to be pragmatic about alternatives to PVC in medicine blister packs.

Moberg Has US Ambitions For Novel Nail Fungus Treatment

 
• By Tom Gallen

Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.